Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Primatene Firm Expects Approval, Counts On Brand Equity, Target Market

This article was originally published in The Tan Sheet

Executive Summary

Amphastar Pharmaceuticals expects FDA to approve an amended NDA for Primatene HFA in 2016. Executives with the firm say sales of breath-triggered Primatene HFA could exceed annual revenues from the original Primatene Mist metered-dose inhaler before it was pulled from the market in 2011.


Related Content

Chronic Conditions Data Emphasize Need For Additional, Innovative OTCs
Asthma Drug Petition Opposes OTC Approach, NSURE Paradigm
Armstrong Juggles Reformulating Primatene Mist, Pushing To Sell Existing Inventory


Related Companies